AI주식인사이트AI Stock Insight
B

셀레믹스

331920KOSDAQ기초 의약물질 제조업

61.8 / 100

Reference Date: 2026-04-13

Financial Score19.0 / 40
News Sentiment13.8 / 25
Momentum17.0 / 20
Disclosure12.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Surged 150.6% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Cellomics is a company specializing in DNA sequencing and molecular cloning technologies based on molecular biology, utilizing its innovative MSSIC (Massively Separated and Sequence Identified Cloning) technology to enable low-cost, high-throughput analysis. The company offers key products such as Target Capture kits, immune repertoire analysis solutions, and next-generation sequencing solutions, which are widely used in healthcare, pharmaceuticals, agriculture, and other fields.

Number of Employees

41people

Average Salary

60.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 33.454.0Point
PBR
5.60Industry Average 2.030.0Point

2.8x industry avg (risky)

ROE
-16.08Industry Average -4.293.5Point

3.7x industry avg (excellent)

Debt Ratio
0.48Industry Average 6.618.0Point

Half of industry avg (excellent)

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼6.0% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼3.8% (2-year basis)

ROE Trend
3.0 / 4

Avg ROE 6.1% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 1Negative 0Average Sentiment Score 60

Detailed Momentum

52-week position8.0Point

Near 52w high (100%, uptrend)

Current 15,790Won52-week high 15,79052-week low 2,580
1-month return6.0Point

1m +150.63% (strong rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

26 totalPositive 1Neutral 25Negative 0
  • Positive주요사항보고서(유상증자결정)2026-04-01
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
  • Neutral주요사항보고서(전환사채권발행결정)2026-03-31
  • Neutral[기재정정]의결권대리행사권유참고서류2026-03-26
  • Neutral[기재정정]주주총회소집공고2026-03-26